Found 16 clinical trials
Belimumab Treatment for IgG4-related Disease
during the treatment. Belimumab is an IgG1-lambda monoclonal antibody that prevents the survival of B lymphocytes by blocking the binding of soluble human B lymphocyte stimulator protein (BLyS) to
- 0 views
- 27 Jan, 2021
- 1 location
A Phase 1 Evaluation of the Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)
infections. Low levels of CD4 cells may make a person more likely to get sick. There are no approved treatments for ICL. Researchers think a drug called belimumab may be able to help in specific situations
- 109 views
- 17 Oct, 2022
- 1 location
Synergetic B-cell Immunomodulation in SLE - 2nd Study. (SynBioSe-2)
-cell targeting by starting treatment with belimumab (anti-BAFF) followed by rituximab(anti-CD20) in lupus nephritis patients.
- 28 views
- 27 Apr, 2022
- 4 locations
BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR T cells in patients with relapsed and/or refractory SLE.
- 0 views
- 04 Oct, 2022
- 1 location
The BeLimumab Antiphospholipid Syndrome Trial (BLAST) (BLAST)
AIM: The primary objective of the BeLimumab Antiphospholipid Syndrome Trial (BLAST) is to evaluate the safety and tolerability of belimumab for up to 24 months in patients with persistent aPL
- 40 views
- 05 Jun, 2022
- 1 location
Belimumab in Patients With Chronic Lymphocytic Leukemia (BeliVeR)
This study is a phase II trial of belimumab in combination with rituximab/venetoclax in patients with refractory or relapsed chronic lymphocytic leukemia (CLL). Treatment of CLL has drastically
- 0 views
- 25 Mar, 2022
Efficacy and Safety of Belimumab in SLE Patients
problems. Belimumab is the only FDA-approved biological agent for SLE. Data showed that treatment with belimumab on the background of standard therapy was effective in active SLE patients. However, the
- 0 views
- 14 Jun, 2022
- 1 location
Rituximab and Belimumab Combination Therapy in PR3 Vasculitis (COMBIVAS)
Mechanistic study to assess whether dual B-cell immunotherapy by co-administration of rituximab and belimumab will result in improvements in biological endpoints, functional outcomes and
- 19 views
- 09 Feb, 2022
- 1 location
Sequential Belimumab and T-cell Based Therapy in SLE
are produced by a specific type of white blood cells called B cells. Belimumab (Benlysta®) is a monoclonal antibody against the B cells by blocking the action of BLyS, a protein that prolongs the
- 0 views
- 23 Dec, 2021
- 1 location
Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders
Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel. Belimumab (Benlysta ®) is a human
- 0 views
- 28 May, 2022
- 1 location
- 1
- 2